8,695
Views
88
CrossRef citations to date
0
Altmetric
Coronaviruses

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies

, , , , , , , , , , , & ORCID Icon show all
Pages 477-481 | Received 27 Dec 2021, Accepted 12 Jan 2022, Published online: 04 Feb 2022

Figures & data

Figure 1. Neutralization of pseudotyped WT (D614G) and Omicron (B.1.1.529) viruses by convalescent sera (a), sera collected at day 14 post 2-dose BBIBP-CorV (b), sera collected before vs. at day 14 post the booster dose (c), and sera collected at day 14 post-BBIBP-CorV or -ZF001 booster dose (d). For all panels, values above the symbols denote geometric mean titer and the numbers in parentheses denote the proportion of positive sera with ID50 above the LOQ (dotted lines, >1:50). P values were determined by using a Wilcoxon matched-pairs signed-rank test (two-tailed).

Figure 1. Neutralization of pseudotyped WT (D614G) and Omicron (B.1.1.529) viruses by convalescent sera (a), sera collected at day 14 post 2-dose BBIBP-CorV (b), sera collected before vs. at day 14 post the booster dose (c), and sera collected at day 14 post-BBIBP-CorV or -ZF001 booster dose (d). For all panels, values above the symbols denote geometric mean titer and the numbers in parentheses denote the proportion of positive sera with ID50 above the LOQ (dotted lines, >1:50). P values were determined by using a Wilcoxon matched-pairs signed-rank test (two-tailed).

Figure 2. Neutralization of pseudotyped WT (D614G) and Omicron (B.1.1.529) viruses by mAbs targeting different epitopes.

Figure 2. Neutralization of pseudotyped WT (D614G) and Omicron (B.1.1.529) viruses by mAbs targeting different epitopes.
Supplemental material

Supplemental Material

Download MS Word (599.2 KB)

Data availability

Materials used in this study will be made available but may require execution of a materials transfer agreement. All the data are provided in the paper or the Supplementary Information.